Document 0805
 DOCN  M9590805
 TI    High-dose pentoxifylline in patients with AIDS: inhibition of tumor
       necrosis factor production. National Institute of Allergy and Infectious
       Diseases AIDS Clinical Trials Group.
 DT    9509
 AU    Dezube BJ; Lederman MM; Spritzler JG; Chapman B; Korvick JA; Flexner C;
       Dando S; Mattiacci MR; Ahlers CM; Zhang L; et al; Department of
       Medicine, Beth Israel Hospital, Boston, MA 02215,; USA.
 SO    J Infect Dis. 1995 Jun;171(6):1628-32. Unique Identifier : AIDSLINE
       MED/95287063
 AB    Tumor necrosis factor-alpha (TNF) may activate human immunodeficiency
       virus (HIV), antagonize zidovudine activity, and contribute to AIDS
       wasting syndrome. Pentoxifylline decreases TNF production. In cell
       culture, pentoxifylline decreases HIV replication and gene expression.
       Since an AIDS Clinical Trial Group study suggested that pentoxifylline
       (400 mg thrice daily) is safe in AIDS patients and decreases TNF mRNA
       levels in peripheral blood mononuclear cells (PBMC), a second cohort
       received 800 mg thrice daily for 8 weeks. During treatment, the median
       decrease in TNF production by PBMC cultured with 0.1 microgram/mL
       lipopolysaccharide (LPS) was 40%. The median change in TNF mRNA was a
       34% decrease. Pentoxifylline did not affect HIV levels as detected by
       quantitative microculture or serum p24 antigen measurements, nor did it
       alter zidovudine pharmacokinetics. The most common toxicity was
       gastrointestinal. Pentoxifylline at dosages of less than thrice-daily
       800 mg is well tolerated and may decrease TNF mRNA levels and
       LPS-induced TNF production.
 DE    beta 2-Microglobulin/METABOLISM  Acquired Immunodeficiency
       Syndrome/*DRUG THERAPY  Biopterin/ANALOGS & DERIVATIVES/BLOOD  Body
       Weight/DRUG EFFECTS  CD4 Lymphocyte Count  Drug Therapy, Combination
       Gene Expression/DRUG EFFECTS  Human  Pentoxifylline/*ADMINISTRATION &
       DOSAGE/PHARMACOKINETICS/TOXICITY  RNA, Messenger/GENETICS  Support,
       Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  Triglycerides/BLOOD  Tumor
       Necrosis Factor/BIOSYNTHESIS/GENETICS  CLINICAL TRIAL  JOURNAL ARTICLE
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).